Concurrent Endostar, Paclitaxel/Carboplatin and Radiotherapy for Locally Advanced Non-small Cell Lung (RT0902)
Status:
Unknown status
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
Concomitant chemoradiotherapy is the standard treatment of locally advanced, non-resectable,
non-small cell lung cancer (NSCLC). However, the optimal chemotherapy regimen is still
controversial. The purpose of this study was to evaluate the efficacy and toxicity of a
concomitant treatment using Endostar (Recombinant Human Endostatin), Paclitaxel/Carboplatin
and radiotherapy for LA-NSCLC, and also assess its impact on patient Quality of Life (QoL)
and progression-free survival (PFS).
Phase:
Phase 2
Details
Lead Sponsor:
Zhejiang Cancer Hospital
Treatments:
Albumin-Bound Paclitaxel Carboplatin Endostar protein Endostatins Paclitaxel